Erik Kyler
Optometrist · Osceola, IANPI 1770745614
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Coopervision Inc. at 58.5% of the total. Reporting peaked in 2023 at $2,077 and has fallen 82.9% since, to $354 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $47.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$3K
- Alcon$741
- Johnson & Johnson Vision Care, Inc.$424
- Amgen$213
- Bausch & Lomb, A Division Of Bausch Health US, LLC$211
- Bausch & Lomb Americas Inc.$184
- plus $595 from 12 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$1,50026%
- Travel & lodging$89516%
- Food & beverage$3,27657%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 36 | $3,339 |
| Alcon | 26 | $741 |
| Johnson & Johnson Vision Care, Inc. | 21 | $424 |
| Amgen | 2 | $213 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $211 |
| Bausch & Lomb Americas Inc. | 6 | $184 |
| Tarsus Pharmaceuticals, Inc. | 4 | $170 |
| AbbVie(2 entities) | 4 | $96 |
| Biotissue Holdings Inc. | 3 | $72 |
| Quidel Corporation | 1 | $50 |
| Maculogix, Inc. | 2 | $46 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Dompe US, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$2,661
- TEPEZZA$125
- Precision 1$123
- XDEMVY$120
- MIEBO$106
How this compares
$5,708 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 41 | $441 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $93 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Osceola
- Sara ButterworthCoralville$191K
- Ethan HuismanWaukee$111K
- Kelsi SawatzkyWest Des Moines$26K
- Heidi BellClive$19K
- Jennifer DenhartogClive$16K
- Wendianne WilsonUrbandale$14K
- Daniel KoenigAmes$11K
- Lexie FranzeenWest Des Moines$7K
- Mallori PhillipsGrimes$7K
- Gabrielle MageeWaukee$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.